{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreih7nauftfd4xp6bh5fzaewqu4ogh5krpx4wywbecgicmfrwi5ekim",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3me6f4os5pea2"
  },
  "path": "/2026/02/06/everest-medicines-announces-china-nmpa-approval-of-velsipity-for-adults-with-moderately-to-severely-active-ulcerative-colitis/",
  "publishedAt": "2026-02-06T05:10:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "SHANGHAI, Feb. 6, 2026 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China’s National Medical Products Administration (NMPA) has approved VELSIPITY® (etrasimod arginine tablets) for the treatment of adult patients with moderately to severely active […]",
  "title": "Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis"
}